Peripheral Vascular Disease (PVD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Factors Associated With Physical Inactivity of Recipients of a Kidney Transplant: Results From the ADHERE BRAZIL Multicenter Study
CONCLUSIONS: This study identified factors associated with physical inactivity after kidney transplantation that may guide future multilevel behavioral change interventions for physical activity.IMPACT: In a multicenter sample of recipients of a kidney transplant with a prevalence of physical inactivity of 69%, we found associations between this behavior and patient- and center-level factors. At the patient level, the chance of physical inactivity was positively associated with smoking, obesity, and patient morbidity (peripheral vascular disease and hospitalization events after kidney transplantation). Conversely, a high f...
Source: Physical Therapy - April 9, 2024 Category: Physiotherapy Authors: Emiliana S Sertorio Fernando A B Colugnati Kris Denhaerynck Stefan De Smet Jose O P Medina Maycon M Reboredo Sabina De Geest Helady Sanders-Pinheiro None On Behalf Of The Adhere Brazil Study Team Source Type: research

Factors Associated With Physical Inactivity of Recipients of a Kidney Transplant: Results From the ADHERE BRAZIL Multicenter Study
CONCLUSIONS: This study identified factors associated with physical inactivity after kidney transplantation that may guide future multilevel behavioral change interventions for physical activity.IMPACT: In a multicenter sample of recipients of a kidney transplant with a prevalence of physical inactivity of 69%, we found associations between this behavior and patient- and center-level factors. At the patient level, the chance of physical inactivity was positively associated with smoking, obesity, and patient morbidity (peripheral vascular disease and hospitalization events after kidney transplantation). Conversely, a high f...
Source: Health Physics - April 9, 2024 Category: Physics Authors: Emiliana S Sertorio Fernando A B Colugnati Kris Denhaerynck Stefan De Smet Jose O P Medina Maycon M Reboredo Sabina De Geest Helady Sanders-Pinheiro None On Behalf Of The Adhere Brazil Study Team Source Type: research

Medium-term outcomes of treatment with a VIABAHN VBX covered stent for aortoiliac occlusive lesions in patients with peripheral artery disease
Endovascular treatment (EVT) for aortoiliac (AI) occlusive lesions is now conducted worldwide, but there are challenges in EVT for complex AI lesions. The VIABAHN VBX (W.L. Gore& Associates, Flagstaff, AZ) is a next-generation balloon-expandable covered stent designed for use with complex AI lesions. The purpose of this study is to evaluate the medium-term outcomes of VIABAHN VBX for such lesions. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - April 9, 2024 Category: Surgery Authors: Maeda Kazuki, Taira Kobayashi, Shogo Emura, Takanobu Okazaki, Shingo Mochizuki, Tomoyasu Sato, Masato Taniguchi, Daisuke Futagami, Risa Inoue, Mayu Tomota, Toshifumi Hiraoka, Takashi Shimonaga, Hitoshi Tachibana, Haruna Shimizu, Shinya Takahashi Tags: Clinical Research Source Type: research

New approaches to triglyceride reduction: Is there any hope left?
Am J Prev Cardiol. 2024 Mar 22;18:100648. doi: 10.1016/j.ajpc.2024.100648. eCollection 2024 Jun.ABSTRACTTriglycerides play a crucial role in the efficient storage of energy in the body. Mild and moderate hypertriglyceridemia (HTG) is a heterogeneous disorder with significant association with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and peripheral artery disease and represents an important component of the residual ASCVD risk in statin treated patients despite optimal low-density lipoprotein cholesterol reduction. Individuals with severe HTG (>1,000 mg/dL) rarely d...
Source: Atherosclerosis - April 8, 2024 Category: Cardiology Authors: Annalisa Filtz Siddhant Parihar Garred S Greenberg Christine M Park Andrea Scotti Daniel Lorenzatti Juan J Badimon Daniel E Soffer Peter P Toth Carl J Lavie Vera Bittner Salim S Virani Leandro Slipczuk Source Type: research

Peripheral Artery Disease: Past and Future
Circulation. 2024 Apr 9;149(15):1151-1153. doi: 10.1161/CIRCULATIONAHA.123.065470. Epub 2024 Apr 8.NO ABSTRACTPMID:38588332 | DOI:10.1161/CIRCULATIONAHA.123.065470 (Source: Circulation)
Source: Circulation - April 8, 2024 Category: Cardiology Authors: Mary M McDermott Source Type: research

Management of claudicants with low toe-brachial index in a Veteran population
CONCLUSION: Patients presenting with claudication and low TBI, especially with diabetes, are at a higher risk to develop chronic limb threatening ischemia. Claudicants with a low TBI should have closer follow-up and more aggressive risk factor modification to reduce long-term mortality.PMID:38588174 | DOI:10.1177/17085381241246309 (Source: Vascular)
Source: Vascular - April 8, 2024 Category: Surgery Authors: Drew Bromenshenkel Clay Quint Source Type: research

Anticoagulation in patients with premature peripheral artery disease undergoing lower extremity revascularization
Premature peripheral artery disease (PAD), defined by lower extremity revascularization (LER) at age ≤ 50 years, is associated with poor major adverse limb events. The early onset of disease is thought to be influenced by genetic factors that regulate homeostasis of the vascular wall and coagulation. The aim of this study is to investigate the effect of anticoagulation as an adjunct to antiplatel et therapy on the outcomes of LER in patients with premature PAD. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - April 7, 2024 Category: Surgery Authors: Tanner I. Kim, Andrew DeWan, Michael Murray, He Wang, Arya Mani, Carlos Mena-Hurtado, Raul J. Guzman, Cassius Iyad Ochoa Chaar Tags: Clinical Research Source Type: research

Common Criticisms and Rebuttals of The BEST-CLI Trial
Peripheral artery disease (PAD) affects more than 230 million patients world-wide1 and its prevalence is increasing due to the aging world population and the epidemic of diabetes and metabolic syndrome. 2 Approximately 11% of those with PAD progress to chronic limb threatening ischemia (CLTI), the most severe form of chronic PAD3 that presents with non-healing wounds or ischemic rest pain4. Without revascularization, the rate of limb loss among those with CLTI is approximately 22% per year.5 In addition, patients with CLTI have a 2-year mortality rate as high as 40% and the risk of death is nearly 3-fold among those with m...
Source: Annals of Vascular Surgery - April 7, 2024 Category: Surgery Authors: Olivia D ’Angelo, Matthew T. Menard, Alik Farber Source Type: research

Development and evaluation of a prediction model for peripheral artery disease related major adverse limb events using novel biomarker data
Prognostic tools for individuals with peripheral artery disease (PAD) remain limited. We developed prediction models for 3-year PAD related major adverse limb events (MALE) using demographic, clinical, and biomarker data previously validated by our group. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - April 7, 2024 Category: Surgery Authors: Ben Li, Rakan Nassereldine, Abdelrahman Zamzam, Muzammil H. Syed, Muhammad Mamdani, Mohammed Al-Omran, Rawand Abdin, Mohammad Qadura Source Type: research

Development and evaluation of a prediction model for peripheral artery disease-related major adverse limb events using novel biomarker data
Prognostic tools for individuals with peripheral artery disease (PAD) remain limited. We developed prediction models for 3-year PAD-related major adverse limb events (MALE) using demographic, clinical, and biomarker data previously validated by our group. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - April 7, 2024 Category: Surgery Authors: Ben Li, Rakan Nassereldine, Abdelrahman Zamzam, Muzammil H. Syed, Muhammad Mamdani, Mohammed Al-Omran, Rawand Abdin, Mohammad Qadura Source Type: research

Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease
CONCLUSIONS: In a real-world population of 4.4 million adults, there are roughly 20,000 new cases of ASVCD diagnosed yearly, with ∼40% being eligible for the addition of low-dose rivaroxaban therapy to antiplatelet therapy. The theoretical implementation of dual antithrombotic treatment in this population could result in a substantial reduction in cardiovascular morbidity and mortality.PMID:38582637 | DOI:10.1016/j.atherosclerosis.2024.117486 (Source: Atherosclerosis)
Source: Atherosclerosis - April 6, 2024 Category: Cardiology Authors: Robert C Welsh Pishoy Gouda Doug Dover Kevin R Bainey Finlay A McAlister Padma Kaul Source Type: research

Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease
Ann Vasc Surg. 2024 Apr 4:S0890-5096(24)00156-0. doi: 10.1016/j.avsg.2024.01.031. Online ahead of print.ABSTRACTPeripheral artery disease (PAD), a highly prevalent global disease, associates with significant morbidity and mortality in affected patients. Despite progress in endovascular and open revascularization techniques for advanced PAD, these interventions grapple with elevated rates of arterial restenosis and vein graft failure attributed to intimal hyperplasia (IH). Novel multi-omics technologies, coupled with sophisticated analyses tools recently powered by advances in artificial intelligence, have enabled the study...
Source: Atherosclerosis - April 6, 2024 Category: Cardiology Authors: Phillip G Brennan Lucas Mota Tarek Aridi Nyah Patel Patric Liang Christiane Ferran Source Type: research